MX2021013248A - Regimenes de dosificacion para anticuerpos anti-vrs y composiciones que los incluyen. - Google Patents

Regimenes de dosificacion para anticuerpos anti-vrs y composiciones que los incluyen.

Info

Publication number
MX2021013248A
MX2021013248A MX2021013248A MX2021013248A MX2021013248A MX 2021013248 A MX2021013248 A MX 2021013248A MX 2021013248 A MX2021013248 A MX 2021013248A MX 2021013248 A MX2021013248 A MX 2021013248A MX 2021013248 A MX2021013248 A MX 2021013248A
Authority
MX
Mexico
Prior art keywords
dosage regimens
present disclosure
disclosure describes
compositions including
rsv antibodies
Prior art date
Application number
MX2021013248A
Other languages
English (en)
Spanish (es)
Inventor
Anis Ahmed Khan
Vadryn Pierre
Original Assignee
Medimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Ltd filed Critical Medimmune Ltd
Publication of MX2021013248A publication Critical patent/MX2021013248A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/11—Paramyxoviridae (F); Pneumoviridae (F), e.g. respiratory syncytial virus [RSV]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
MX2021013248A 2019-04-30 2020-04-30 Regimenes de dosificacion para anticuerpos anti-vrs y composiciones que los incluyen. MX2021013248A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962840701P 2019-04-30 2019-04-30
PCT/US2020/030619 WO2020223435A1 (en) 2019-04-30 2020-04-30 Dosage regimens for and compositions including anti-rsv antibodies

Publications (1)

Publication Number Publication Date
MX2021013248A true MX2021013248A (es) 2022-01-24

Family

ID=70779897

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021013248A MX2021013248A (es) 2019-04-30 2020-04-30 Regimenes de dosificacion para anticuerpos anti-vrs y composiciones que los incluyen.

Country Status (15)

Country Link
US (3) US12024553B2 (cg-RX-API-DMAC7.html)
EP (1) EP3962940A1 (cg-RX-API-DMAC7.html)
JP (2) JP2022531205A (cg-RX-API-DMAC7.html)
KR (1) KR20220002427A (cg-RX-API-DMAC7.html)
CN (1) CN113825767A (cg-RX-API-DMAC7.html)
AU (1) AU2020265676A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021020846A2 (cg-RX-API-DMAC7.html)
CA (1) CA3138180A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021014370A2 (cg-RX-API-DMAC7.html)
EA (1) EA202192776A1 (cg-RX-API-DMAC7.html)
IL (1) IL287443A (cg-RX-API-DMAC7.html)
MX (1) MX2021013248A (cg-RX-API-DMAC7.html)
SG (1) SG11202111748TA (cg-RX-API-DMAC7.html)
TW (1) TWI861099B (cg-RX-API-DMAC7.html)
WO (1) WO2020223435A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI911431B (zh) * 2017-03-01 2026-01-11 英商梅迪繆思有限公司 抗rsv單株抗體配製物
KR20240055097A (ko) * 2021-09-13 2024-04-26 메디뮨 리미티드 니르세비맙을 사용한 호흡기 세포융합 바이러스 하기도 감염의 예방
EP4588936A4 (en) * 2022-12-08 2026-08-12 Changchun Bcht Biotechnology Co ANTIBODIES THAT BIND SPECIFICALLY TO VRS
CN121846262A (zh) * 2026-01-05 2026-04-14 上海生物制品研究所有限责任公司 抗呼吸道合胞病毒单克隆抗体制剂

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
PE20091174A1 (es) * 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
RS60056B1 (sr) 2013-02-01 2020-04-30 Medimmune Llc Epitopi f proteina respiratornog sincicijalnog virusa
FR3008921B1 (fr) 2013-07-23 2015-12-25 Safran Piece en materiau composite avec portion de conductivite thermique et electrique et procede de fabrication d'une telle piece
RS60387B1 (sr) 2014-01-15 2020-07-31 Medimmune Llc Rsv-specifična antitela i njihovi funkcionalni delovi
TWI911431B (zh) 2017-03-01 2026-01-11 英商梅迪繆思有限公司 抗rsv單株抗體配製物
JP2020509025A (ja) 2017-03-01 2020-03-26 メドイミューン・リミテッドMedImmune Limited モノクローナル抗体製剤

Also Published As

Publication number Publication date
TW202106333A (zh) 2021-02-16
WO2020223435A1 (en) 2020-11-05
EP3962940A1 (en) 2022-03-09
CA3138180A1 (en) 2020-11-05
BR112021020846A2 (pt) 2022-01-18
JP2025072444A (ja) 2025-05-09
IL287443A (en) 2021-12-01
US20220204593A1 (en) 2022-06-30
US12024553B2 (en) 2024-07-02
EA202192776A1 (ru) 2022-01-19
US20200347120A1 (en) 2020-11-05
KR20220002427A (ko) 2022-01-06
US20240417447A1 (en) 2024-12-19
CN113825767A (zh) 2021-12-21
JP2022531205A (ja) 2022-07-06
AU2020265676A1 (en) 2021-11-18
CO2021014370A2 (es) 2021-10-29
TWI861099B (zh) 2024-11-11
SG11202111748TA (en) 2021-11-29

Similar Documents

Publication Publication Date Title
CO2021014370A2 (es) Regímenes de dosificación para anticuerpos anti-vrs y composiciones que los incluyen
CL2020002075A1 (es) Métodos para tratar el cáncer con anticuerpos anti-pd1.
MX2019011117A (es) Anticuerpo b7-h3, fragmento de union a antigeno de los mismos y uso medico de los mismos.
CR20190162A (es) Métodos para usar un anticuerpo biespecífico que reconoce el factor de coagulación ix y/o el factor de coagulación ix activado y el factor de coagulación x y/o el factor de coagulación x activado
MX2017006312A (es) Metodos para el tratamiento tumoral utilizando el anticuerpo biespecifico cd3xcd20.
MX393855B (es) Terapia de combinación que comprende un inhibidor de raf y trametinib
MX2022001841A (es) Anticuerpos contra ilt2 y uso de los mismos.
CY1122792T1 (el) Παραγωγα μονο- ή δισυποκατεστημενης ινδολης ως αναστολεις αναδιπλασιασμου δαγκειου ιου
MX2019010994A (es) Metodos para tratar enfermedades y trastornos mediados por el complemento.
MX2017000627A (es) Metodos para tratar pacientes con hipercolesterolemia familiar heterocigota (hfhe).
BR112021015036A2 (pt) Tratamento para câncer com imunoconjugados do anticorpo ror1
JOP20220104A1 (ar) نظام تجريع لعوامل مضادة لـ dll3
AR050418A1 (es) Dosificacion fija de anticuerpos her
GEAP202516662A (en) Anti-nectin-4 antibody, conjugate including same, and application thereof
CO2019010295A2 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
CL2017001756A1 (es) Régimen de dosificación para antagonistas de madcam.
MX2022002636A (es) Tratamiento de la enfermedad o trastorno hepatico que comprende los antagonistas del receptor de actrii.
MX2023000187A (es) Dosificacion de vibegron para el tratamiento de vejiga sobreactiva.
MX2021004120A (es) Regimen de dosificacion para antagonistas de tfpi.
MX2022001065A (es) Anticuerpo anti-bcma, fragmento de union al antigeno y uso medico del mismo.
CL2019003533A1 (es) Uso de vibegron para tratar vejiga sobreactiva.
MX2023004554A (es) Uso de benzodiazepinas para aumentar la sensibilidad a la psilocibina despues de un regimen cronico de isrs.
BR112023026992A2 (pt) Medicamento para o tratamento e/ou prevenção do câncer, agentes que aumentam a eficácia do medicamento em uma composição farmacêutica e método para tratar e/ou prevenir o câncer
AR119159A1 (es) Tratamientos de angioedema
ECSP23076276A (es) Métodos para el tratamiento del cáncer con administración subcutánea de anticuerpos anti-pd1